CD40LG and cardiovascular disorder: A number of small studies involving patients with diabetes have shown that several of these drugs can significantly reduce sCD40L levels [89,90]; however, these drugs have been associated with hepatotoxicity and an increased risk of cardiovascular disease, and thus, may not be suitable for use as an adjunctive therapy in HIV infection.